USD 4.23
(-10.19%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -2.73 Million USD | 0.33% |
2022 | -3.1 Million USD | -23.89% |
2021 | -2.19 Million USD | -11.58% |
2020 | -2.2 Million USD | -18.58% |
2019 | -1.85 Million USD | -18.58% |
2018 | -1.56 Million USD | -139.82% |
2017 | -653 Thousand USD | 57.6% |
2016 | -1.54 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -757 Thousand USD | 26.72% |
2024 Q2 | -968 Thousand USD | -11.21% |
2023 Q1 | -848 Thousand USD | -50.62% |
2023 Q3 | -576 Thousand USD | 20.33% |
2023 Q2 | -723 Thousand USD | 14.74% |
2023 FY | - USD | 0.33% |
2023 Q4 | -1.09 Million USD | -90.28% |
2022 Q3 | -1.01 Million USD | -47.02% |
2022 Q2 | -687 Thousand USD | 12.37% |
2022 Q1 | -784 Thousand USD | 11.61% |
2022 Q4 | -563 Thousand USD | 44.26% |
2022 FY | - USD | -23.89% |
2021 Q4 | -887 Thousand USD | -92.83% |
2021 Q1 | -493 Thousand USD | 26.96% |
2021 Q2 | -377 Thousand USD | 23.53% |
2021 Q3 | -460 Thousand USD | -22.02% |
2021 FY | - USD | -11.58% |
2020 Q2 | -521 Thousand USD | -4.41% |
2020 Q1 | -499 Thousand USD | -67.45% |
2020 Q4 | -675 Thousand USD | -40.04% |
2020 FY | - USD | -18.58% |
2020 Q3 | -482 Thousand USD | 7.49% |
2019 Q2 | -1.06 Million USD | -83.74% |
2019 FY | - USD | -18.58% |
2019 Q4 | -298 Thousand USD | -463.41% |
2019 Q3 | 82 Thousand USD | 107.72% |
2019 Q1 | -578 Thousand USD | -21.94% |
2018 FY | - USD | -139.82% |
2018 Q3 | -666 Thousand USD | -132.06% |
2018 Q4 | -474 Thousand USD | 28.83% |
2018 Q1 | -294 Thousand USD | -147.06% |
2018 Q2 | -287 Thousand USD | 2.38% |
2017 FY | - USD | 57.6% |
2017 Q4 | -119 Thousand USD | 0.0% |
2016 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Akoya Biosciences, Inc. | -45.63 Million USD | 94.017% |
AngioDynamics, Inc. | -14.29 Million USD | 80.898% |
AtriCure, Inc. | -8.1 Million USD | 66.334% |
Avinger, Inc. | -16.34 Million USD | 83.299% |
Azenta, Inc. | 55.15 Million USD | 104.95% |
BioLife Solutions, Inc. | -45.23 Million USD | 93.965% |
The Cooper Companies, Inc. | 882.8 Million USD | 100.309% |
Daxor Corporation | 329.74 Thousand USD | 927.925% |
Ekso Bionics Holdings, Inc. | -13.19 Million USD | 79.315% |
Femasys Inc. | -13.16 Million USD | 79.27% |
GlucoTrack, Inc. | -7.09 Million USD | 61.5% |
Harvard Bioscience, Inc. | 9.49 Million USD | 128.758% |
Hologic, Inc. | 1.29 Billion USD | 100.211% |
ICU Medical, Inc. | 307.69 Million USD | 100.887% |
Intuitive Surgical, Inc. | 2.39 Billion USD | 100.114% |
KORU Medical Systems, Inc. | -9.39 Million USD | 70.956% |
LeMaitre Vascular, Inc. | 48.99 Million USD | 105.573% |
Innovative Eyewear, Inc. | -6.57 Million USD | 58.48% |
Innovative Eyewear, Inc. | -6.57 Million USD | 58.48% |
Masimo Corporation | 236.7 Million USD | 101.153% |
Microbot Medical Inc. | -10.63 Million USD | 74.328% |
Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 117.311% |
Merit Medical Systems, Inc. | 231.44 Million USD | 101.18% |
Nephros, Inc. | -1.37 Million USD | -97.97% |
NovoCure Limited | -175.86 Million USD | 98.448% |
NEXGEL, Inc. | -2.73 Million USD | -0.0% |
Singular Genomics Systems, Inc. | -86.49 Million USD | 96.844% |
OraSure Technologies, Inc. | 76.15 Million USD | 103.585% |
Pro-Dex, Inc. | 8.33 Million USD | 132.761% |
Pulse Biosciences, Inc. | -42.36 Million USD | 93.556% |
Predictive Oncology Inc. | -13.18 Million USD | 79.29% |
Precision Optics Corporation, Inc. | -2.51 Million USD | -8.68% |
QuidelOrtho Corporation | 545.6 Million USD | 100.5% |
Repligen Corporation | 124.29 Million USD | 102.196% |
Sanara MedTech Inc. | -289.09 Thousand USD | -844.32% |
STAAR Surgical Company | 33.22 Million USD | 108.218% |
Sharps Technology, Inc. | -8.98 Million USD | 69.6% |
Utah Medical Products, Inc. | 24.8 Million USD | 111.006% |
DENTSPLY SIRONA Inc. | 232 Million USD | 101.177% |
Jin Medical International Ltd. | 3.44 Million USD | 179.294% |